Becton, Dickinson and Company (BDX): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

Based in New Jersey, Becton, Dickinson and Company BDX is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

Becton operates through three business segments: BD Medical, BD Diagnostics, and BD Biosciences.

BD Medical (53.5% of total revenues in fiscal 2013): The segment company offers hypodermic syringes and needles for injection insulin syringes, pen needles, and blood glucose monitoring systems for diabetes care infusion therapy devices prefillable drug delivery systems surgical blades and scalpels and thermometers. This segment also offers safety-engineered sharps products (injection, infusion, and surgery devices) and anesthesia, ophthalmology, critical care, medication management and sharps disposal products.

BD Diagnostics (32.9%): The major products in the segment are clinical and industrial microbiology products, safety-engineered specimen collection products, specimen management systems, molecular diagnostic instruments and other diagnostic systems, including immunodiagnostic test kits and healthcare consulting services.

BD Biosciences (13.6%): This segment provides products and services for a variety of applications in life sciences. The company markets its products worldwide through sales representatives and independent distributors.